Cannabinoid receptor mod 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 
31 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cannabidiol (CBD) / Pure Green
NCT04679545: Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet

Recruiting
2
50
US
CBD, Placebo
Pure Green
Diabetic Peripheral Neuropathic Pain
03/21
04/21
CannEpil (cannabis oil) / MGC Pharma
NCT04406948: Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies

Withdrawn
2
103
Europe, RoW
MGCND00EP1, Cannabis oil, Placebo, ECG, EEG, Blood and urine collection, blood tests
MGC Pharmaceuticals d.o.o
Resistant Epilepsy, Drug, Adolescent Epilepsy, Children Epilepsy, Children and Adolescents With Resistant Epilepsies
05/24
05/24
Trichomylin (fixed-dose cannabinoid formulation) / ZYUS
UTOPIA-1, NCT06533657: Unique Treatment of Oncology Pain in Advanced Cancer

Not yet recruiting
2
20
NA
Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)
ZYUS Life Sciences Inc.
Cancer Pain
11/25
11/25
HOPE, NCT04867057: Trichomylin® Safety, Tolerability & Pharmacokinetics in Healthy Adults and First in Human Osteoarthritis Pain Evaluation

Completed
1
41
RoW
Trichomylin for SAD, Placebo for SAD, Trichomylin for MAD, Placebo for MAD
ZYUS Life Sciences Inc., Novotech (Australia) Pty Limited, ZYUS Life Sciences Australia Pty Ltd
Healthy, Osteoarthritis
02/22
05/22
cannabidiol (BTX 1702) / Botanix Pharma
ACTRN12621000689875: A Randomised, Double-Blind, Vehicle-Controlled Study of the Safety and Tolerability of BTX 1702 in Patients with Papulopustular Rosacea

Completed
1
120
 
Botanix Pharmaceuticals Ltd, Botanix Pharmaceuticals Ltd
Papulopustular Rosacea
 
 
cannabidiol/cannabinol (PG-OA-10CN) / Pure Green
PG-OA-2021, NCT04992962: Cannabinoid Tablets for the Treatment of Pain From Osteoarthritis of the Knee

Recruiting
2
66
US
CBD/CBN, CBD/THC, Placebo
Pure Green
Osteoarthritis, Knee
10/21
11/21
cannabidiol (EMD-RX5) / Emyria
ACTRN12622001319763: A Phase III study to investigate the effect of EMD-RX5 on symptoms of psychological distress in adults with chronic pain

Suspended
3
300
 
Emyria Ltd, Emyria Ltd
Psychological Distress
 
 
ACTRN12622000427774: A Phase I Clinical Trial comparing Pharmacokinetics of EMD-RX5 Cannabidiol (CBD) capsules to Epidyolex CBD oil in Healthy Volunteers.

Completed
1
12
 
Emyria Ltd, Emyria Ltd
psychological distress
 
 
CogniCann (cannabidiol/tetrahydrocannabinol) / MGC Pharma
ACTRN12619000474156: Medicinal cannabis use among dementia patients

Recruiting
1/2
50
 
University of Notre Dame Australia, MGC pharmaceuticals Ltd
Dementia
 
 
cannabidiol (CHI-554) / Canopy Growth
NCT05317507: Safety of Co-Administered CHI-554 and Alcohol

Completed
1
29
US
CBD oil, Placebo
Auburn University
Healthy Adults
03/23
03/23
IrniCann (cannabidiol/cannabigerol) / MGC Pharma
NCT07016971: CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy

Not yet recruiting
1
12
US
CBG/CBD Oil
Milton S. Hershey Medical Center
Chemotherapy-Induced Peripheral Neuropathy
01/28
02/28
delta-9-tetrahydrocannabinol/cannabidiol (TN-TC11G) / Tilray
GEINOCANN, NCT03529448: TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma

Active, not recruiting
1/2
33
Europe
TN-TC11G, Temozolomide Oral Product, Temozolomide, Radiotherapy, STUPP
Grupo Español de Investigación en Neurooncología, Medical Cannabis Bike Tour, Voices Against Brain Cancer, Tilray
Glioblastoma
03/25
12/25
adezunap (AP707) / CannaXan, Apurano Pharma
NCT06071988: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy

Recruiting
3
558
Europe
Adezunap (AP707), Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Neuropathic Pain, Peripheral Neuropathy, Peripheral Neuralgia, Peripheral Nerve Injury, Post Operative Pain, Post-Traumatic Neuralgia, Plexopathy
09/24
12/24
NCT06071936: Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy

Recruiting
3
558
Europe
Adezunap (AP707), Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Neuropathic Pain, Peripheral Neuropathy, Peripheral Neuralgia, Peripheral Nerve Injury, Post Operative Pain, Post-Traumatic Neuralgia, Plexopathy
09/24
12/24
NCT06071949: Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis

Recruiting
3
558
Europe
Adezunap, Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Neuropathic Pain, Central Neuropathic Pain, Paraplegia, Multiple Sclerosis, Stroke, Phantom Limb Syndrome With Pain, Phantom Pain, Traumatic Brain Injury
09/24
12/24
NCT06071962: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain

Recruiting
3
558
Europe
Adezunap (AP707), Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Back Pain, Lower Back Pain, Lower Back Pain Chronic
09/24
12/24
NCT06071975: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy

Recruiting
3
558
Europe
Adezunap (AP707), Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Diabetes, Diabetic Neuropathies, Diabetic Polyneuropathy, Peripheral Neuralgia, Peripheral Neuropathy, Peripheral Neuropathy With Type 2 Diabetis
09/24
12/24
NCT06072001: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis

Recruiting
3
558
Europe
Adezunap (AP707), Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Neuropathic Pain, Central Neuropathic Pain, Paraplegia, Multiple Sclerosis, Stroke, Phantom Limb Syndrome With Pain, Phantom Pain, Traumatic Brain Injury
09/24
12/24
NCT06072560: Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain

Recruiting
3
558
Europe
Adezunap (AP707), Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Back Pain, Lower Back Pain, Lower Back Pain Chronic
09/24
12/24
NCT06072573: Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy

Recruiting
3
558
Europe
Adezunap (AP707), Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Diabetes, Diabetic Neuropathies, Diabetic Polyneuropathy, Peripheral Neuralgia, Peripheral Neuropathy, Peripheral Neuropathy With Type 2 Diabetis
09/24
12/24
NTI164 / Neurotech International
ACTRN12622001398796: Evaluating the Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in Young People with Autism Spectrum Disorder, a Double-Blind, Randomised and Controlled-to-Open-Label Study.

Not yet recruiting
2/3
54
 
Fenix Innovation Group, Fenix Innovation Group, Neurotech International Limited
Autism Spectrum Disorder
 
 
NCT05626959: Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder

Not yet recruiting
2/3
54
RoW
NTI164, Full-spectrum medicinal cannabis plant extract 0.08% THC
Fenix Innovation Group, Neurotech International, Monash Health
Autism Spectrum Disorder
03/23
11/23
ACTRN12622001419752: Investigating the effects of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) on paediatric acute-onset neuropsychiatric syndrome (PANS): An open-label study.

Not yet recruiting
1/2
15
 
Fenix Innovation Group, Fenix Innovation Group, Neurotech International Limited
Paediatric acute-onset neuropsychiatric syndrome
 
 
ACTRN12621000760875p: Evaluating the Safety and Efficacy of Full-Spectrum Medicinal Cannabis (FEN164) in Children with ASD.

Not yet recruiting
1/2
20
 
Fenix Innovation Group, Fenix Innovation Group
Autism Spectrum Disorder
 
 
ACTRN12623000563662: A Phase I/II study to assess the safety and efficacy of full-spectrum medicinal cannabis plant extract 0.08% THC (NTI164) in the treatment of Rett syndrome (RTT)

Recruiting
1/2
14
 
Fenix Innovation Group, Fenix Innovation Group, Neurotech International Limited
Rett Syndrome
 
 
ACTRN12621000760875: Evaluating the Safety and Efficacy of Full-Spectrum Medicinal Cannabis (FEN164) in Children with ASD.

Active, not recruiting
1/2
20
 
Fenix Innovation Group, Fenix Innovation Group, Neurotech International Limited
Autism Spectrum Disorder
 
 
NCT05516407: Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.

Active, not recruiting
1/2
18
RoW
FEN164
Fenix Innovation Group, Neurotech International, Monash Health
Autism Spectrum Disorder
09/22
09/22
CannaPANS, NCT06621888: Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS)

Active, not recruiting
1/2
18
RoW
NTI164
Fenix Innovation Group, Neurotech International
PANS Pediatric Acute-Onset Neuropsychiatric Syndrome
12/25
12/25
NCT06621043: Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT)

Active, not recruiting
1/2
14
RoW
NTI164
Fenix Innovation Group, Neurotech International
Rett Syndrome
12/25
12/25
NCT06713447: NTI164 Human PK Study

Active, not recruiting
1
12
RoW
NTI164
Fenix Innovation Group, CMAX Clinical Research Pty Ltd, Neurotech International Limited
Healthy, Healthy Volunteer
06/25
06/25
cannabidiol/tetrahydrocannabinol (T2:C100) / MediPharm Labs, University of Southern California
LiBBY, NCT05644262: Life's End Benefits of cannaBidiol and tetrahYdrocannabinol

Recruiting
2
150
US
T2:C100, TRC/CBD oral combination, Placebo
University of Southern California, Medical University of South Carolina, Alzheimer's Clinical Trials Consortium, Alzheimer's Therapeutic Research Institute, National Institute on Aging (NIA)
Agitation, Dementia
12/25
12/25
RHO Phyto Transdermal CBG Gel (cannabidiol/cannabigerol) / Avicanna
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cannabidiol (CBD) / Pure Green
NCT04679545: Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet

Recruiting
2
50
US
CBD, Placebo
Pure Green
Diabetic Peripheral Neuropathic Pain
03/21
04/21
CannEpil (cannabis oil) / MGC Pharma
NCT04406948: Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies

Withdrawn
2
103
Europe, RoW
MGCND00EP1, Cannabis oil, Placebo, ECG, EEG, Blood and urine collection, blood tests
MGC Pharmaceuticals d.o.o
Resistant Epilepsy, Drug, Adolescent Epilepsy, Children Epilepsy, Children and Adolescents With Resistant Epilepsies
05/24
05/24
Trichomylin (fixed-dose cannabinoid formulation) / ZYUS
UTOPIA-1, NCT06533657: Unique Treatment of Oncology Pain in Advanced Cancer

Not yet recruiting
2
20
NA
Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)
ZYUS Life Sciences Inc.
Cancer Pain
11/25
11/25
HOPE, NCT04867057: Trichomylin® Safety, Tolerability & Pharmacokinetics in Healthy Adults and First in Human Osteoarthritis Pain Evaluation

Completed
1
41
RoW
Trichomylin for SAD, Placebo for SAD, Trichomylin for MAD, Placebo for MAD
ZYUS Life Sciences Inc., Novotech (Australia) Pty Limited, ZYUS Life Sciences Australia Pty Ltd
Healthy, Osteoarthritis
02/22
05/22
cannabidiol (BTX 1702) / Botanix Pharma
ACTRN12621000689875: A Randomised, Double-Blind, Vehicle-Controlled Study of the Safety and Tolerability of BTX 1702 in Patients with Papulopustular Rosacea

Completed
1
120
 
Botanix Pharmaceuticals Ltd, Botanix Pharmaceuticals Ltd
Papulopustular Rosacea
 
 
cannabidiol/cannabinol (PG-OA-10CN) / Pure Green
PG-OA-2021, NCT04992962: Cannabinoid Tablets for the Treatment of Pain From Osteoarthritis of the Knee

Recruiting
2
66
US
CBD/CBN, CBD/THC, Placebo
Pure Green
Osteoarthritis, Knee
10/21
11/21
cannabidiol (EMD-RX5) / Emyria
ACTRN12622001319763: A Phase III study to investigate the effect of EMD-RX5 on symptoms of psychological distress in adults with chronic pain

Suspended
3
300
 
Emyria Ltd, Emyria Ltd
Psychological Distress
 
 
ACTRN12622000427774: A Phase I Clinical Trial comparing Pharmacokinetics of EMD-RX5 Cannabidiol (CBD) capsules to Epidyolex CBD oil in Healthy Volunteers.

Completed
1
12
 
Emyria Ltd, Emyria Ltd
psychological distress
 
 
CogniCann (cannabidiol/tetrahydrocannabinol) / MGC Pharma
ACTRN12619000474156: Medicinal cannabis use among dementia patients

Recruiting
1/2
50
 
University of Notre Dame Australia, MGC pharmaceuticals Ltd
Dementia
 
 
cannabidiol (CHI-554) / Canopy Growth
NCT05317507: Safety of Co-Administered CHI-554 and Alcohol

Completed
1
29
US
CBD oil, Placebo
Auburn University
Healthy Adults
03/23
03/23
IrniCann (cannabidiol/cannabigerol) / MGC Pharma
NCT07016971: CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy

Not yet recruiting
1
12
US
CBG/CBD Oil
Milton S. Hershey Medical Center
Chemotherapy-Induced Peripheral Neuropathy
01/28
02/28
delta-9-tetrahydrocannabinol/cannabidiol (TN-TC11G) / Tilray
GEINOCANN, NCT03529448: TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma

Active, not recruiting
1/2
33
Europe
TN-TC11G, Temozolomide Oral Product, Temozolomide, Radiotherapy, STUPP
Grupo Español de Investigación en Neurooncología, Medical Cannabis Bike Tour, Voices Against Brain Cancer, Tilray
Glioblastoma
03/25
12/25
adezunap (AP707) / CannaXan, Apurano Pharma
NCT06071988: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy

Recruiting
3
558
Europe
Adezunap (AP707), Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Neuropathic Pain, Peripheral Neuropathy, Peripheral Neuralgia, Peripheral Nerve Injury, Post Operative Pain, Post-Traumatic Neuralgia, Plexopathy
09/24
12/24
NCT06071936: Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy

Recruiting
3
558
Europe
Adezunap (AP707), Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Neuropathic Pain, Peripheral Neuropathy, Peripheral Neuralgia, Peripheral Nerve Injury, Post Operative Pain, Post-Traumatic Neuralgia, Plexopathy
09/24
12/24
NCT06071949: Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis

Recruiting
3
558
Europe
Adezunap, Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Neuropathic Pain, Central Neuropathic Pain, Paraplegia, Multiple Sclerosis, Stroke, Phantom Limb Syndrome With Pain, Phantom Pain, Traumatic Brain Injury
09/24
12/24
NCT06071962: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain

Recruiting
3
558
Europe
Adezunap (AP707), Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Back Pain, Lower Back Pain, Lower Back Pain Chronic
09/24
12/24
NCT06071975: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy

Recruiting
3
558
Europe
Adezunap (AP707), Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Diabetes, Diabetic Neuropathies, Diabetic Polyneuropathy, Peripheral Neuralgia, Peripheral Neuropathy, Peripheral Neuropathy With Type 2 Diabetis
09/24
12/24
NCT06072001: Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis

Recruiting
3
558
Europe
Adezunap (AP707), Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Neuropathic Pain, Central Neuropathic Pain, Paraplegia, Multiple Sclerosis, Stroke, Phantom Limb Syndrome With Pain, Phantom Pain, Traumatic Brain Injury
09/24
12/24
NCT06072560: Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain

Recruiting
3
558
Europe
Adezunap (AP707), Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Back Pain, Lower Back Pain, Lower Back Pain Chronic
09/24
12/24
NCT06072573: Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy

Recruiting
3
558
Europe
Adezunap (AP707), Placebo
Apurano Pharmaceuticals GmbH
Pain, Pain Syndrome, Pain, Chronic, Chronic Pain, Chronic Pain Syndrome, Diabetes, Diabetic Neuropathies, Diabetic Polyneuropathy, Peripheral Neuralgia, Peripheral Neuropathy, Peripheral Neuropathy With Type 2 Diabetis
09/24
12/24
NTI164 / Neurotech International
ACTRN12622001398796: Evaluating the Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in Young People with Autism Spectrum Disorder, a Double-Blind, Randomised and Controlled-to-Open-Label Study.

Not yet recruiting
2/3
54
 
Fenix Innovation Group, Fenix Innovation Group, Neurotech International Limited
Autism Spectrum Disorder
 
 
NCT05626959: Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder

Not yet recruiting
2/3
54
RoW
NTI164, Full-spectrum medicinal cannabis plant extract 0.08% THC
Fenix Innovation Group, Neurotech International, Monash Health
Autism Spectrum Disorder
03/23
11/23
ACTRN12622001419752: Investigating the effects of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) on paediatric acute-onset neuropsychiatric syndrome (PANS): An open-label study.

Not yet recruiting
1/2
15
 
Fenix Innovation Group, Fenix Innovation Group, Neurotech International Limited
Paediatric acute-onset neuropsychiatric syndrome
 
 
ACTRN12621000760875p: Evaluating the Safety and Efficacy of Full-Spectrum Medicinal Cannabis (FEN164) in Children with ASD.

Not yet recruiting
1/2
20
 
Fenix Innovation Group, Fenix Innovation Group
Autism Spectrum Disorder
 
 
ACTRN12623000563662: A Phase I/II study to assess the safety and efficacy of full-spectrum medicinal cannabis plant extract 0.08% THC (NTI164) in the treatment of Rett syndrome (RTT)

Recruiting
1/2
14
 
Fenix Innovation Group, Fenix Innovation Group, Neurotech International Limited
Rett Syndrome
 
 
ACTRN12621000760875: Evaluating the Safety and Efficacy of Full-Spectrum Medicinal Cannabis (FEN164) in Children with ASD.

Active, not recruiting
1/2
20
 
Fenix Innovation Group, Fenix Innovation Group, Neurotech International Limited
Autism Spectrum Disorder
 
 
NCT05516407: Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.

Active, not recruiting
1/2
18
RoW
FEN164
Fenix Innovation Group, Neurotech International, Monash Health
Autism Spectrum Disorder
09/22
09/22
CannaPANS, NCT06621888: Investigating The Effects Of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) On Paediatric Acute-onset Neuropsychiatric Syndrome (PANS)

Active, not recruiting
1/2
18
RoW
NTI164
Fenix Innovation Group, Neurotech International
PANS Pediatric Acute-Onset Neuropsychiatric Syndrome
12/25
12/25
NCT06621043: Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT)

Active, not recruiting
1/2
14
RoW
NTI164
Fenix Innovation Group, Neurotech International
Rett Syndrome
12/25
12/25
NCT06713447: NTI164 Human PK Study

Active, not recruiting
1
12
RoW
NTI164
Fenix Innovation Group, CMAX Clinical Research Pty Ltd, Neurotech International Limited
Healthy, Healthy Volunteer
06/25
06/25
cannabidiol/tetrahydrocannabinol (T2:C100) / MediPharm Labs, University of Southern California
LiBBY, NCT05644262: Life's End Benefits of cannaBidiol and tetrahYdrocannabinol

Recruiting
2
150
US
T2:C100, TRC/CBD oral combination, Placebo
University of Southern California, Medical University of South Carolina, Alzheimer's Clinical Trials Consortium, Alzheimer's Therapeutic Research Institute, National Institute on Aging (NIA)
Agitation, Dementia
12/25
12/25
RHO Phyto Transdermal CBG Gel (cannabidiol/cannabigerol) / Avicanna
No trials found

Download Options